Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 07, 2023

BUY
$8.48 - $16.48 $50,133 - $97,429
5,912 New
5,912 $97,000
Q4 2021

Feb 09, 2022

SELL
$7.34 - $11.18 $57,185 - $87,103
-7,791 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$5.03 - $7.95 $13,581 - $21,465
-2,700 Reduced 25.74%
7,791 $52,000
Q3 2020

Nov 13, 2020

BUY
$5.02 - $8.98 $52,664 - $94,209
10,491 New
10,491 $52,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Wolverine Asset Management LLC Portfolio

Follow Wolverine Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Asset Management LLC with notifications on news.